Atossa Therapeutics (ATOS) Stock: Buy, Sell, or Hold?
ATOS - Atossa Therapeutics, Inc. Common Stock
$2.51
0.17 (7.26%)
â˛
5d:
-0.79%
30d:
+6.81%
90d:
-2.9%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When ATOS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ATOS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ATOS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ATOS is currently trading at $2.51, which is considered fair relative to its 30-day fair value range of $2.40 to $2.63.
Technical Outlook: Technically, ATOS is in a strong downtrend. Immediate support is located at $2.32, while resistance sits at $2.62. The stock is showing strong short-term momentum, up 7.3% recently.
Market Sentiment: ATOS scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.67 (+643.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ATOS is in a strong downtrend. Immediate support is located at $2.32, while resistance sits at $2.62. The stock is showing strong short-term momentum, up 7.3% recently.
Market Sentiment: ATOS scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.67 (+643.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.40 -
$2.63
Company Quality Score
38/100
(SELL)
Options IV Signal
40th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
58.3%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Options fairly priced (IV 40th percentile)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.3%)
- BULLISH: Trading 643.7% below Wall St target ($18.67)
- WARNING: Composite score 38/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.40 -
$2.63
Current vs Trading Range
FAIR
Expected Move (7 Days)
Âą$0.47
(18.6%)
Support & Resistance Levels
Support Level
$2.32
Resistance Level
$2.62
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.57
Wall Street Target
$18.67
(+643.7%)
Share & Embed Analysis
Last updated: September 13, 2026 12:21 PM ET
Data refreshes hourly during market hours. Next update: 1:21 PM
Data refreshes hourly during market hours. Next update: 1:21 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATOS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
|
RNA
Atrium Therapeutics, IncâĻ |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
